ClinicalTrials.gg

Program

islatravir

Also written as “Islatravir”, “DOR/ISL” and “ISL”.

Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Infections, led by 2 companies.

Furthest: phase 3, since Jan 8, 202028 company-led studies, 8 open or runningNext primary completion: Aug 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck277 open or runningphase 3since Jan 8, 2020Aug 13, 2014Aug 10, 2027phase 2 · NCT06891066
Gilead Sciences11 open or runningphase 2since Sep 13, 2021Sep 13, 2021none ahead
  • Named in Merck’s own pipeline as islatravir + lenacapavir (MK-8591D), phase 3, as of Nov 2, 2026 (source).
  • Named in Merck’s own pipeline as islatravir + ulonivirine (MK-8591B), phase 2, as of Nov 2, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Aug 13, 2014.

  1. Nov 23, 2020Phase 3 study in Acquired Immunodeficiency SyndromeMerck · NCT04644029 · 730 enrolled · United States, South Africa, Uganda
  2. Dec 2, 2020Phase 3 study in HIV Preexposure ProphylaxisMerck · NCT04652700 · 494 enrolled · United States, Brazil, France and more
  3. Sep 13, 2021Gilead Sciences's first study: phase 2 study in HIV-1 InfectionNew to Gilead SciencesGilead Sciences · NCT05052996 · 142 enrolled · United States
  4. Nov 2, 20212 phase 2 studies in Acquired Immunodeficiency SyndromeMerck · NCT05115838, NCT05130086
  5. Nov 18, 20222 phase 3 studies in HIV-1 InfectionMerck · NCT05631093, NCT05630755
  6. Jan 20, 2023Phase 3 study in HIV-1 InfectionMerck · NCT05705349 · 537 enrolled · United States, Argentina, Canada and more
  7. Mar 1, 2023Phase 3 study in HIV InfectionsMerck · NCT05766501 · 641 enrolled · United States, Argentina, Australia and more
  8. Sep 27, 2024Phase 1 study in HealthyMerck · NCT06619678 · 36 enrolled · United States
  9. Dec 2, 2024Phase 1 study in HealthyMerck · NCT06719570 · 24 enrolled · United States
  10. Jan 31, 2025Phase 1 study in HealthyMerck · NCT06811246 · 20 enrolled · United States
  11. Mar 17, 2025Phase 2 study in Acquired Immunodeficiency SyndromeMerck · NCT06891066 · 150 enrolled · United States, Australia, Puerto Rico and more
  12. Jul 18, 2025Phase 1 study in HealthyMerck · NCT07086079 · 12 enrolled · United States
  13. Dec 1, 2025Phase 3 study in Acquired Immunodeficiency SyndromeMerck · NCT07266831 · 570 planned · United States, Argentina, Canada and more
  14. Oct 2, 2026Phase 2 study in HIV InfectionsMerck · NCT07862569 · 45 planned

Ahead

  1. Aug 10, 2027Primary completion: phase 2 study in Acquired Immunodeficiency SyndromeMerck · NCT06891066
  2. Feb 1, 2029Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeMerck · NCT07266831
  3. Sep 24, 2029Primary completion: phase 2 study in HIV InfectionsMerck · NCT07862569

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07862569HIV Infections2Not yet recruitingMerckSep 24, 202945
NCT07266831Acquired Immunodeficiency Syndrome · United States, Argentina, Canada and more3RecruitingMerckFeb 1, 2029570
NCT07086079Healthy · United States1CompletedMerckDec 8, 202512
NCT06891066Acquired Immunodeficiency Syndrome · United States, Australia, Puerto Rico and more2Active, not recruitingMerckAug 10, 2027150
NCT06811246Healthy · United States1CompletedMerckJul 14, 202420
NCT06719570Healthy · United States1CompletedMerckMar 15, 202424
NCT06619678Healthy · United States1CompletedMerckJun 23, 202436
NCT05766501HIV Infections · United States, Argentina, Australia and more3Active, not recruitingMerckOct 16, 2025641
NCT05705349HIV-1 Infection · United States, Argentina, Canada and more3Active, not recruitingMerckOct 13, 2025537
NCT05631093HIV-1 Infection · United States, Australia, Canada and more3Active, not recruitingMerckOct 10, 2024553
NCT05630755HIV-1 Infection · United States, Australia, Chile and more3Active, not recruitingMerckOct 25, 2024514
NCT05130086Acquired Immunodeficiency Syndrome2WithdrawnMerckMar 25, 20240
NCT05115838Acquired Immunodeficiency Syndrome2WithdrawnMerckOct 2, 20250
NCT05052996HIV-1 Infection · United States2Active, not recruitingGilead SciencesDec 19, 2023142
NCT04652700HIV Preexposure Prophylaxis · United States, Brazil, France and more3TerminatedMerckAug 4, 2023494
NCT04644029Acquired Immunodeficiency Syndrome · United States, South Africa, Uganda3TerminatedMerckJul 18, 2023730
NCT04568603HIV-1 Infection · United States1CompletedMerckJul 9, 202114
NCT04564547HIV-1 Infection · United States, France, Switzerland2CompletedMerckJan 30, 2025161
NCT04515641Acquired Immunodeficiency Syndrome · United States1CompletedMerckSep 13, 202112
NCT04303156Acquired Immunodeficiency Syndrome · United States, Germany1CompletedMerckOct 19, 202012
NCT04295772HIV-1 Infection · United States, Italy, Russian Federation and more2CompletedMerckDec 21, 202142
NCT04233879HIV-1 Infection · United States, Argentina, Canada and more3CompletedMerckNov 17, 2022599
NCT04233216HIV-1 Infection · United States, Australia, Canada and more3CompletedMerckNov 21, 202235
NCT04223791HIV Infections · United States, Australia, Austria and more3CompletedMerckAug 26, 2021643
NCT04223778HIV Infections · United States, Australia, Canada and more3CompletedMerckSep 8, 2021672
NCT04003103HIV-1 Infection · United States, Israel, South Africa2CompletedMerckMar 18, 2022242
NCT03272347HIV-1 Infection · United States, Chile, France and more2CompletedMerckMar 8, 2021123
NCT02217904HIV-11CompletedMerckMay 11, 201730

How it is read

Names in the registry

  • “Islatravir”, 11 entries
  • “DOR/ISL”, 11 entries
  • “ISL”, 5 entries
  • “Islatravir (ISL)”, 1 entry
  • “Doravirine/Islatravir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.